Oral Session 1-9A Maliginant lymphoma: Basic (1)

[OS1-9A-2] Recurrent MYC alteration in BPDCN: association with immunoblastoid morphology and drug response

Kana Sakamoto^1,2, Ryohei Katayama³, Reimi Asaka^1,4, Seiji Sakata¹, Satoko Baba¹, Hideki Nakasone², Sumie Koike³, Naoko Tsuyama⁴, Akito Dobashi¹, Makoto Sasaki⁵, Ryo Ichinohasama⁶, Emi Takakuwa⁷, Rie Yamazaki⁸, Jun Takizawa⁹, Takahiro Maeda¹⁰, Miwako Narita¹¹, Koji Izutsu¹², Yoshinobu Kanda², Koichi Ohshima¹³, Kengo Takeuchi^1,4 (1.Pathology Project for Molecular Targets, Cancer Institute, JFCR, Tokyo, Japan, 2.Div. Hematol., Jichi Medical University Saitama Medical Center, Saitama, Japan, 3.Division of Experimental Chemotherapy, Cancer Chemotherapy Center, JFCR, Tokyo, Japan, 4.Division of Pathology, The Cancer Institute, JFCR, Tokyo, Japan, 5.Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan, 6.Dept. Hematopathology, Tohoku University Graduate School of Medicine, Sendai, Japan, 7.Dept. Surg. Pathol., Hokkaido Univ. Hosp., Sapporo, Japan, 8.Division of Hematology, Keio University School of Medicine, Tokyo, Japan, 9.Dept. Hematology/Endocrinology/Metabolism, Niigata Univ. Faculty of Medicine, Niigata, Japan, 10.Department of General Medicine, Nagasaki University Graduate School, Nagasaki, Japan, 11.Laboratory of Hematology and Oncology, Niigata University, Niigata, Japan, 12.Department of Hematology, National Cancer Center Hospital, Tokyo, Japan, 13.Department of Pathology, School of Medicine, Kurume University, Kurume, Japan)